ライフサイエンスコーパス: syncope

1 inued treatment because of an adverse event (syncope).

2 or cardiac failure, atrial fibrillation, and syncope).

3 y disease, acute pancreatitis, hip fracture, syncope).

4 on [AF], and 4% with a history of arrhythmic syncope).

5 haemorrhage, severe anaemia, and cardiogenic syncope).

6 tomatic patients (n = 101), 15 had BCEs (all syncopes).

7 rare, serious, and often treatable cause of syncope.

8 ictal asystole episodes, 15 of which led to syncope.

9 eactions (6 were hypotensive) and 6 reported syncope.

10 ode of aborted sudden death, and 8 (20%) had syncope.

11 table cardioverter defibrillator shocks, and syncope.

12 unaltered (placebo) followed by LBNP to pre-syncope.

13 a future role in the management of falls and syncope.

14 abdominal pains, breathing difficulties, and syncope.

15 ty, with no apparent increase in the risk of syncope.

16 d ventricular tachycardia, or arrhythmogenic syncope.

17 tween 2006 and 2012 for diagnostic workup of syncope.

18 apy, and the use of pacemakers for vasovagal syncope.

19 ts without previous comorbidity admitted for syncope.

20 tifies AS patients with an increased risk of syncope.

21 lization, device implantation, and recurrent syncope.

22 for the relatively benign neurally mediated syncope.

23 c vasoconstriction in neurally mediated (pre)syncope.

24 ents with severe asystolic neurally mediated syncope.

25 l vascular resistance may contribute to (pre)syncope.

26 ity, and the remaining 6 addressed vasovagal syncope.

27 ears with severe asystolic neurally mediated syncope.

28 ctive pacing, and only 1 reported subsequent syncope.

29 matic relatives experienced exercise-induced syncope.

30 es among adult patients with reflex-mediated syncope.

31 ruction and symptoms of dyspnea, angina, and syncope.

32 presenting to the emergency department with syncope.

33 ia, orthostatic hypotension, and uncommonly, syncope.

34 risk subset of LQTS patients presenting with syncope.

35 lude dyspnoea, chest pain, palpitations, and syncope.

36 he identification of high-risk patients with syncope.

37 QT syndrome (LQTS) patients presenting with syncope.

38 of structural heart disease, arrhythmia, and syncope.

39 in patients with cardioinhibitory vasovagal syncope.

40 A 45-year-old woman presented with syncope.

41 patients hospitalized for a first episode of syncope.

42 outcome measure was the first recurrence of syncope.

43 but without postural lightheadedness or near syncope.

44 being on fludrocortisone prevents vasovagal syncope.

45 class, Canadian Cardiology Society class, or syncope.

46 there were alternative explanations for the syncope.

47 se neurological symptoms such as vertigo and syncope.

48 ystole>6 s is strongly associated with ictal syncope.

49 ed palpitations, 47% fatigue, and 30% (near-)syncope.

50 chycardia [6], near-drowning [2], exertional syncope [1], symptoms on therapy [2], LQT3 [1], QTc>520

51 cities included neutropenia (34%), vasovagal syncope (10%), hypertension (7%), nausea/vomiting (7%),

52 luding non-specific chest pain, dyspnoea and syncope (1368 [6%] deaths), and respiratory disorders (2

53 hospital discharge had a higher incidence of syncope (16.0% vs. 0.7%; p = 0.001) and complete AVB req

54 capture after implantation: 1 has recurrent syncope, 2 eventually died.

55 The end point consisted of (1) syncope, (2) symptomatic presyncopal episodes associated

56 5.6 years; 26 male), resulting in presyncope/syncope (25 patients), hemodynamic collapse (3 patients)

57 and 28.9% for controls; P=0.045), presyncope/syncope (27.8% for cases and 21.3% for controls; P<0.001

58 ly different between groups in time to first syncope: 29.2 months (95% CI: 15.3 to 29.2 months) versu

59 sudden cardiac death were presyncope (61%), syncope (31%), previous cardiac arrest (14%), ventricula

60 y incontinence (18.5% vs 3.9%; P = .04), and syncope (37% vs 9.6%; P = .01) did not hold up after cor

61 ccessfully clamped at baseline levels at pre-syncope (38.3 +/- 2.7 vs. 38.5 +/- 2.5 mmHg respectively

62 acebo group and the 2.5 mg-maximum group was syncope (4% and 1%, respectively).

63 Prior syncope (4.1%), documented arrhythmia (3.4%), and family

64 nonsustained ventricular tachycardia (46%), syncope (41%), and abnormal blood pressure response (25%

65 , 34 400 (95% CI, 31 200-37 600) episodes of syncope, 43 400 (95% CI, 39 400-47 500) serious electrol

66 ing tachycardia, and these patients had more syncope (5/11 [45%] versus 0/15 [0%]; P<0.01), slower or

67 ntrols, patients with DAPs had more frequent syncope (5/26 [19%] versus 3/73 [4%]; P=0.02) and ventri

68 cohort study of 153 patients with vasovagal syncope, 52 of whom received beta-blockers.

69 55% female) who had undergone stress MPI for syncope; 659 patients (94%) had normal perfusion.

70 cated (preoperative evaluation, 63% vs. 37%; syncope, 69% vs. 31%; P < 0.001 for each).

71 53%), 25 were preoperatively symptomatic (15 syncope, 7 near-drowning, and 3 resuscitated sudden deat

72 Nonsustained ventricular tachycardia, syncope, a family history of sudden cardiac death, and s

73 and related to the risk for cardiac events (syncope, aborted cardiac arrest, and sudden cardiac deat

74 ith a 1% to 5% annual risk of LQTS-triggered syncope, aborted cardiac arrest, or sudden cardiac death

75 etine prevents arrhythmic events (arrhythmic syncope, aborted cardiac arrest, or sudden cardiac death

76 tive in reducing the risk of cardiac events (syncope, aborted cardiac arrest, sudden cardiac death).

77 ge: 34.0+/-13.8 years) with cardioinhibitory syncope, advanced atrioventricular block or sinus arrest

78 severity AEs were reported in two subjects; syncope after a single 250 mg dose (one subject) and abd

79 In contrast, patients experiencing syncope after starting beta-blocker therapy had a 3.6-fo

80 IEW: This review examines recent research on syncope after whole blood donation and efforts by blood

81 The first admission for syncope among healthy individuals significantly predicts

82 ,017 patients with a first-time diagnosis of syncope and 185,085 control subjects; their median age w

83 ope beyond patients with recurrent vasovagal syncope and asystole documented by implantable loop reco

84 efit of pacing among patients with recurrent syncope and asystole documented by implantable loop reco

85 tentially life-threatening symptoms, such as syncope and end-stage organ hypoperfusion.

86 Prior syncope and family history of sudden death are predictor

87 Potential mechanistic links between syncope and future manifestation with PEA warrant furthe

88 2.7%) who had an alternative explanation for syncope and in 52 of the 205 patients (25.4%) who did no

89 inostat 160 mg twice daily: one (2%) grade 3 syncope and one (2%) grade 3 myalgia event in different

90 uld explore novel ways to reduce the risk of syncope and prevent the uncommon, but potentially seriou

91 re, whether pacing reduces risk of recurrent syncope and relevant clinical outcomes among adult patie

92 dered during the evaluation of syncope, near-syncope and seizures, especially in the setting of exerc

93 in patients with emergency presentations of syncope and should now be subjected to external validati

94 History of syncope and spontaneous type I ECG (hazard ratio [HR]: 4

95 S) is an arrhythmogenic disorder that causes syncope and sudden death.

96 ycardia is characterized by stress-triggered syncope and sudden death.

97 2%) and 14,251 (7.1%) deaths occurred in the syncope and the control population, respectively, yieldi

98 sociated with higher risk include unheralded syncope and the presence of a spontaneous type 1 electro

99 Disproportional reporting of syncope and venous thromboembolic events was noted with

100 remained asymptomatic, 39 (11.2%) developed syncope, and 32 (9.2%) developed VF/SCD.

101 diac arrest survivors, 27 had presented with syncope, and 59 were asymptomatic.

102 decline but are associated with hypotension, syncope, and greater medication burden.

103 Angina, exertional syncope, and heart failure are key symptoms indicating a

104 4%, and 61% of patients with cardiac arrest, syncope, and no symptoms, respectively.

105 ion can lead to decompensated heart failure, syncope, and sudden cardiac death.

106 oventricular block, presenting clinically as syncope, and sudden death.

107 eased risk of tachyarrhythmia, palpitations, syncope, and sudden death.

108 ular arrhythmias and atrioventricular block, syncope, and sudden death.

109 d observational studies examining pacing and syncope, and the bibliographies of known systematic revi

110 ted QT interval > or =450 ms presenting with syncope as a first symptom were drawn from the Internati

111 pted sleep at night may have greater risk of syncope as a result of their exposure to postural stress

112 liminary data have shown that a standardized syncope assessment, especially when coupled with interac

113 Some patients with PAH have a history of syncope at presentation.

114 ress, leading to increased susceptibility to syncope at specific times of day.

115 Forty-five (12%) patients had a history of syncope at the time of PAH diagnosis.

116 lass, family history of sudden death (FHSD), syncope, atrial fibrillation, non-sustained ventricular

117 leads to paroxysmal dizziness, fatigue, and syncope because of a temporarily or permanently reduced

118 upport the use of pacing for reflex-mediated syncope beyond patients with recurrent vasovagal syncope

119 DDD-CLS pacing significantly reduced syncope burden and time to first recurrence by 7-fold, p

120 diate- to high-risk patients presenting with syncope but not for low-risk patients.

121 cts (age 15-51) with no history of recurrent syncope but who had presyncope during 60 deg upright til

122 portion of patients with recurrent vasovagal syncope by at least 40%, representing a pre-specified mi

123 ortisone reduced the likelihood of vasovagal syncope by the specified risk reduction of 40%.

124 s who experienced recurrent exertion-induced syncope/cardiac arrest beginning at 1 year of age.

125 ding heart failure, infarction, arrhythmias, syncope, cardiomyopathy, angina, heart transplantation a

126 The origin of 40% of syncope cases remains unknown even after a complete diag

127 ars with head-up tilt test-induced vasovagal syncope compared with sham pacing.

128 toms (headache, numbness, weakness, vertigo, syncope, diplopia, hypotension, floaters, other).

129 ne plasmatic level define a distinct form of syncope, distinguish it from VVS, and suggest a causal r

130 ther at rest or induced by hypocapnia at pre-syncope does not impact OT, probably due to a compensato

131 the PENFS group, two in the sham group), and syncope due to needle phobia (n=1; in the sham group).

132 Patients with syncope during beta-blocker therapy are at high risk of

133 The risk of syncope during beta-blocker therapy is high during child

134 e causes of syncope, the late recurrences of syncope (during > or =6 months of follow-up), and the ov

135 es of serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney inj

136 nd (ii) serious adverse events (hypotension, syncope, electrolyte abnormalities, bradycardia, or acut

137 ower-body negative pressure (LBNP) until pre-syncope; end-tidal carbon dioxide (P ET , CO 2) was clam

138 (HR: 1.74; 95% CI: 1.68 to 1.80), recurrent syncope event rate of 45.1 per 1,000, stroke event rate

139 , and 10 757 (49.5%) employed at time of the syncope event.

140 examined for their relationships with ictal syncope events.

141 The incidence of syncope exhibits a daily pattern with more occurrences i

142 ing that gap are currently under evaluation: syncope facilities with specialist backup and interactiv

143 -up of 72+/-95 months, all patients remained syncope free.

144 ociety class 3 to 4 from 26% to 2%; and with syncope from 25% to 2%.

145 h patients age >/=40 years, with high burden syncope (>/=5 episodes, >/=2 episodes in the past year),

146 o third quartiles, 2.0-4.5), 622 people with syncope had an occupational accident requiring hospitali

147 t of acute heart block; another patient with syncope had intermittent heart block and survived as the

148 syndrome and aborted sudden cardiac death or syncope have higher risks for ventricular arrhythmias (V

149 able analysis, type 1 electrocardiogram with syncope (hazard ratio: 4.96; 95% confidence interval: 1.

150 outcome included previous cardiac arrest or syncope (hazard ratio=3.4; 95% confidence interval, 1.4-

151 0.97-3.09]), 3.0% vs 2.4%, respectively, for syncope (HR, 1.23 [95% CI, 0.76-2.00]), 4.0% vs 2.7% for

152 sone significantly reduced the likelihood of syncope (HR: 0.63; 95% CI: 0.42 to 0.94; p = 0.024).

153 lation (hazard ratio [HR]: 4.38; p = 0.002), syncope (HR: 3.36; p < 0.001), participation in strenuou

154 rs of severe anaphylaxis were defined as (1) syncope, hypotension, or hypoxia; (2) signs and symptoms

155 302 patients with anaphylaxis, 55 (18%) had syncope, hypoxia, or hypotension, 57 (19%) required hosp

156 should be considered in patients with ictal syncope if they are not considered good candidates for e

157 In the cohort study, the hazard ratio for syncope if treated with beta-blockers was 1.54 (95% CI,

158 The risk of death or recurrent syncope, implantation of pacemaker or implantable cardio

159 sudden cardiac death in 6 patients (24%) and syncope in 4 patients (16%).

160 ined whether beta-blockers prevent vasovagal syncope in an age-related fashion.

161 ts without previous comorbidity admitted for syncope in Denmark from 2001 to 2009 were identified in

162 ily history of intermittent palpitations and syncope in his brother raised suspicion for catecholamin

163 eta-blocker treatment may suppress vasovagal syncope in middle-aged patients aged >42 years.

164 The prognostic implications of syncope in PAH have not yet been well characterized.

165 Syncope in PAH is associated with worsening right heart

166 acing is effective in reducing recurrence of syncope in patients >/=40 years with severe asystolic ne

167 he yield of stress MPI for the evaluation of syncope in patients at risk but without known coronary a

168 The presence of syncope in patients with aortic valve stenosis (AS) pred

169 is, only Zva was an independent predictor of syncope in patients with AS (odds ratio, 2.02; 95% confi

170 Therefore, because predictors of syncope in patients with AS have not been investigated i

171 per m(2) as the cutoff value associated with syncope in patients with AS.

172 ocardiographic parameters, including Zva, on syncope in patients with AS.

173 Syncope in patients with bifascicular block (BFB) is a c

174 cing was effective in reducing recurrence of syncope in patients with presumed neurally mediated sync

175 Stress MPI for evaluation of syncope in patients without known coronary artery diseas

176 to determine the prognostic significance of syncope in pulmonary arterial hypertension (PAH).

177 The ROSE (Risk stratification Of Syncope in the Emergency department) rule had a sensitiv

178 was a marginally nonsignificant reduction in syncope in the fludrocortisone group (hazard ratio [HR]:

179 ses had a significantly higher prevalence of syncope in their lifetime, with other correlates, includ

180 The pathophysiology of syncope in these patients is uncertain.

181 n is not the cause of neurally mediated (pre)syncope in this population.

182 little effectiveness in preventing vasovagal syncope in unselected populations, but they might be eff

183 ailure (in 3% of patients in each group) and syncope (in 2% of the riociguat group and in 3% of the p

184 Syncope is a common clinical condition occurring even in

185 Syncope is a common clinical event, but knowledge of pro

186 Syncope is a common clinical problem characterized by tr

187 Syncope is a common, potentially serious condition accou

188 Syncope is a sudden transient loss of consciousness and

189 currences in patients with neurally mediated syncope is controversial.

190 Syncope is highly predictive for future fatal arrhythmia

191 Ictal syncope is more common in left than in right temporal se

192 ary embolism among patients hospitalized for syncope is not well documented, and current guidelines p

193 First, syncope is only 1 of many causes of transient loss of co

194 drocortisone for the prevention of vasovagal syncope; ISRCTN51802652; Prevention of Syncope Trial 2 [

195 tatus; extent of structural disease; cardiac syncope; male sex; the presence of multiple mutations or

196 ears) and had a history of fewer episodes of syncope (median of 2 [interquartile range [IQR]: 1 to 2.

197 All cases of recurrent syncope (n=12) were attributed to a vasovagal (n=10) or

198 ptoms included acute chest pain (n=16, 33%), syncope (n=12, 25%), and sudden death (n=9, 19%) whereas

199 Patients with syncope (n=79; 18%) had higher Zva (5.1+/-0.9 versus 4.4

200 hould be considered during the evaluation of syncope, near-syncope and seizures, especially in the se

201 in patients with presumed neurally mediated syncope (NMS) and documented asystole but syncope still

202 events and could be helpful in investigating syncope not related to VAs.

203 The risk of syncope occurring while driving has obvious implications

204 Whenever syncope occurs despite optimal medical therapy, LCSD cou

205 Prior syncope (odds ratio, 4.0; 95% confidence interval, 1.6-9

206 18 patients (22%) and anemia, headache, and syncope of grade 3 or higher each occurred in 2 patients

207 centers in the Third International Study on Syncope of Uncertain Etiology (ISSUE-3) trial.

208 In the Third International Study on Syncope of Uncertain Etiology (ISSUE-3), cardiac pacing

209 linded ISSUE-3 (Third International Study on Syncope of Uncertain Etiology) trial, which demonstrated

210 ents in patients with bifascicular block and syncope of undetermined origin implanted with permanent

211 In patients with bifascicular block and syncope of undetermined origin, the use of a dual chambe

212 out diagnosed structural heart disease) with syncope of unknown origin and atrioventricular or sinoat

213 tudy suggests that, in elderly patients with syncope of unknown origin and positive ATP tests, active

214 ority trial tested whether, in patients with syncope of unknown origin, selecting cardiac pacing in t

215 ad an aborted cardiac arrest, 2 patients had syncope only, 10 patients had >/=1 appropriate ICD disch

216 Age of onset of major symptoms (syncope or cardiac arrest) ranged from 1 to 9 years.

217 Innocent murmur and syncope or palpitations with no other indications of car

218 The most common problems were syncope or presyncope (37.4% of cases), respiratory symp

219 She denied experiencing fevers, syncope or presyncope, focal neurologic deficits, chest

220 nts (BCEs) were defined as LQTS-attributable syncope or seizures, aborted cardiac arrest, appropriate

221 d to DDD60 led to a significant reduction of syncope or symptomatic events associated with a cardioin

222 with sustained ventricular tachycardia with syncope or systolic heart failure as a result of ischemi

223 y of anxiety (OR 1.90, 95% CI:1.12-3.24) and syncope (OR 2.75, 95% CI:1.45-5.22).

224 ute coronary syndromes, cardiac arrhythmias, syncope, or even sudden cardiac death.

225 ersons with uncomplicated faint, situational syncope, or orthostatic hypotension should receive elect

226 the effects of fludrocortisone in vasovagal syncope over a 1-year treatment period.

227 tions because of hypotension (P < 0.001) and syncope (P = 0.035) with combination therapy compared wi

228 Syncope (P<0.001), cardiac arrest (P<0.001), and treatme

229 f seizures with asystole duration>6 s led to syncope (P=0.02).

230 adian Cardiology Society class (P=0.106), or syncope (P=0.426) after ASA.

231 ported bradycardic adverse events, including syncope, pacemaker placement, and cardiac arrest.

232 Atrial fibrillation, syncope, participation in strenuous exercise after the d

233 recorded cardiopulmonary dynamics in supine syncope patients and healthy volunteers (aged 15-27 year

234 ac pacing was effective in neurally mediated syncope patients with documented asystolic episodes in w

235 of the following: chest/abdominal/back pain, syncope, perfusion deficit, and if AAS was in the differ

236 is, the incidence rate ratio in the employed syncope population was higher than in the employed gener

237 e of 14.3 per 1,000 person-years (PY) in the syncope population.

238 Characterization of ictal syncope predictors may aid in the selection of high-risk

239 est requiring resuscitation (1 death), 5 had syncope/presyncope, and 2 were asymptomatic.

240 artment visits, atrial fibrillation/flutter, syncope/presyncope, end-stage liver disease, malignancy,

241 Of these, 3 events-syncope, pulmonary embolism, and serum creatinine increa

242 symptoms (palpitations, fatigue, and [near-]syncope), PVC burden on 24-hour Holter, NT-proBNP levels

243 tors of RV pathology included the following: syncope; Q waves or precordial QRS amplitudes <1.8 mV; 3

244 ent-years; HR, 0.87; P = .50) and arrhythmic syncope rates (3.1 [95% CI, 2.6-4.6] vs 1.9 [95% CI, 1.1

245 and 26 TT-) with asystolic neurally mediated syncope received a pacemaker.

246 Syncope recurred in 8 of 39 patients (21%) randomized to

247 Syncope recurred in 8 TT+ and in 1 TT- patients.

248 There was syncope recurrence during follow-up in 27 patients, 19 o

249 currence by 7-fold, prolonging time to first syncope recurrence in patients age >/=40 years with head

250 The 2-year estimated syncope recurrence rate was 57% (95% CI, 40-74) with pac

251 At 21 months, the estimated product-limit syncope recurrence rates were 55% and 5%, respectively (

252 TP tests, active dual-chamber pacing reduces syncope recurrence risk by 75% (95% confidence interval,

253 d 32% absolute and 57% relative reduction in syncope recurrence support this invasive treatment for t

254 lowed up regularly for up to 5 years for any syncope recurrence, the primary outcome.

255 ly 14 patients were lost to follow-up before syncope recurrence.

256 Of these, 96 patients had >/=1 syncope recurrences, and only 14 patients were lost to f

257 11 hospitals in Italy for a first episode of syncope, regardless of whether there were alternative ex

258 associated with a 70% reduction in recurrent syncope (relative risk [RR]: 0.30; 95% confidence interv

259 cm s(-1) (31%; P </= 0.001), but time to pre-syncope remained similar between trials (placebo: 1123 +

260 Pacing in vasovagal syncope remains controversial.

261 ogress made, the management of patients with syncope remains largely unsatisfactory because of the pr

262 n-flight medical emergencies were related to syncope, respiratory symptoms, or gastrointestinal sympt

263 [CI, 0.73 to 0.94]) but increase the RR for syncope (RR, 1.24 [CI, 1.02 to 1.52]) and cough (RR, 1.6

264 er defibrillator shock or (2) arrhythmogenic syncope, seizures, or aborted cardiac arrest after LCSD.

265 Long-QT syndrome (LQTS) may result in syncope, seizures, or sudden cardiac arrest.

266 who experienced episodes of exertion-induced syncope since age 10, had normal QT interval, and displa

267 (Closed Loop Stimulation for Neuromediated Syncope [SPAIN Study]; NCT01621464).

268 ed syncope (NMS) and documented asystole but syncope still recurred in 25% of them at 2 years.

269 atients had >2 syncopal spells and a Calgary Syncope Symptom Score >-3.

270 was recognized as a common occurrence during syncope that should not be regarded as indicating epilep

271 The causes of syncope, the late recurrences of syncope (during > or =6

272 ), pulmonary toxic effects (six [24%] vs 0), syncope (three [12%] vs two [8%]), dyspnoea (three [12%]

273 Prevention of syncope through permanent cardiac pacing in patients wit

274 all-cause death in patients presenting with syncope to the emergency department.

275 abnormalities that have been associated with syncope, torsade de pointes arrhythmias, and sudden card

276 participants in the randomized Prevention of Syncope Trial (POST), examining the interaction between

277 vagal syncope; ISRCTN51802652; Prevention of Syncope Trial 2 [POST 2]; NCT00118482).

278 The multicenter POST 2 (Prevention of Syncope Trial 2) was a randomized, placebo-controlled, d

279 ence of a spontaneous type I ECG, history of syncope, ventricular effective refractory period <200 ms

280 e evaluation vignettes and 82% to 85% of the syncope vignettes.

281 se of 31 patients with established vasovagal syncope (VVS).

282 recovery; the most common form is vasovagal syncope (VVS).

283 Syncope was a significant predictor of mortality (hazard

284 In this nationwide cohort, syncope was associated with a 1.4-fold higher risk of oc

285 the uncontrolled trial, yet the time to pre-syncope was comparable between trials (544 +/- 130 vs. 5

286 ly diagnosed heart failure, arrhythmias, and syncope was generally found to be Appropriate or May Be

287 Syncope was more common with left temporal (40%) than wi

288 Presyncope/syncope was more frequent in patients with idiopathic PA

289 No significant difference in the risk of syncope was observed with conventional versus therapy re

290 n the uncontrolled trial, P ET , CO 2 at pre-syncope was reduced by 10.9 +/- 3.9 mmHg (P </= 0.001).

291 A history of syncope was strongly associated with PEA (odds ratio, 2.

292 duals, 21 729 with a first-time diagnosis of syncope were identified, with a median age 48.4 years (f

293 seizure with asystole duration</=6 s led to syncope, whereas 94% (15/16) of seizures with asystole d

294 , and the overall low incidence of recurrent syncope while driving provide useful information to supp

295 p recorder; 89 of these had documentation of syncope with >/=3 s asystole or >/=6 s asystole without

296 We examined the associations of syncope with occupational accidents and termination of e

297 ief guidance on how to manage a patient with syncope, with reference to the above guidelines.

298 h >/=3 s asystole or >/=6 s asystole without syncope within 12 +/- 10 months and met criteria for pac

299 ry findings of 15 patients with sudden-onset syncope without prodromes who had a normal heart and nor

300 indings of patients affected by sudden-onset syncope without prodromes who had a normal heart and nor